ICNMD 2016

July 5 to 9, 2016

Program at a Glance

Tuesday, July 5, 2016

TEACHING COURSES (TC)

- **TC 1.0** Paediatric Muscular Dystrophy — CITY HALL
- **TC 2.0** Myasthenia Gravis — DOMINION NORTH
- **TC 3.0** Genetics — CHURCHILL
- **TC 4.0** Non-immune Mediated Polyneuropathy — SWCOE & DUFFERIN
- **TC 5.0** Ultrasound in Neuromuscular Disorders — DOMINION SOUTH
- **1.1** Dowling: Congenital Myopathies (8:00 - 8:55)
- **2.1** Barnett Tapia: Clinical Assessment of Myasthenia Gravis (8:00 - 8:55)
- **3.1** Cohn: The ABC's of Genetics (8:00 - 8:55)
- **4.1** Reilly: Hereditary Polyneuropathy (8:00 - 8:55)
- **1.2** Flenigan: Dysferlinopathies (8:55 - 9:50)
- **2.2** Querol: Antibody Testing in Myasthenia Gravis (8:55 - 9:50)
- **3.2** Meyn: The Ethical Implementation of Genomic Medicine (8:55 - 9:50)
- **4.2** Russell: Assessment of Neuropathy in Diabetes and Pre-Diabetes (8:55 - 9:50)
- **Lectures**
  - **5.1** Breiner: Introduction to Ultrasound (9:00 - 9:25)
  - **5.2** Walker: Ultrasound of Focal Peripheral Neuropathies (9:25 - 9:50)
  - **5.3** Hobson-Webb: Ultrasound of Diffuse Neuropathies & Motor Neuron Disease (9:50 - 9:15)
  - **5.4** Shook: Ultrasound of Muscle (9:15 - 9:40)
  - Discussion Period (9:40 - 9:50)

Networking Break (9:50 - 10:10)

- **1.3** Shaub: Limb-girdle Dystrophies (10:10 - 11:05)
- **2.3** Katzberg: Electrophysiological Testing in Myasthenia Gravis (10:10 - 11:05)
- **3.2** Reilly: Evaluation of Variants of Unknown Significance (10:10 - 11:05)
- **4.3** Dyck: Treatment of PDEMS (10:10 - 11:05)
- **5.5 Practical Demonstrations** 10:10-10:45 STATION 1; 10:45-11:20 STATION 2; 11:20-11:55 STATION 3
  - STATIONS: 1) Median and ulnar nerves (upper limb); 2) Fibular and tibial nerves (lower limb); 3) Muscle +/- diaphragm (10:10 - 12:00)
- **1.4** Amato: Axial Myopathies (11:05 - 12:00)
- **2.4** Wolfe: Treatment of Myasthenia Gravis (11:05 - 12:00)
- **3.4** McCusig: Genetics Counselling (11:05 - 12:00)
- **4.4** Chapman: Paraneoplastic Neuropathy (11:05 - 12:00)

Networking Break (12:00 - 13:00)

- **TC 6.0** Inflammatory Neuropathies co-sponsored with PNS — CITY HALL
- **TC 7.0** ALS — CHURCHILL
- **TC 8.0** Myopathy — DOMINION NORTH
- **TC 9.0** Autonomic Neuropathy — SWCOE & DUFFERIN
- **TC 10.0** Adult Muscular Dystrophy and Myopathy — DOMINION SOUTH
- **6.1** Lager: Clinical Aspects of Immune Mediated Neuropathies (13:00 - 13:55)
- **7.1** Genge: Evaluation of Patients with ALS (13:00 - 13:55)
- **8.1** Tarnopolsky: Evaluation of Metabolic Myopathy (13:00 - 13:55)
- **9.1** Feldman: Introduction to Autonomic Neuropathy (13:00 - 13:55)
- **10.1** Tseng: Update on Fascio-Scapulo-Humeral Dystrophy (FSHD) (13:00 - 13:55)
- **6.2** Merkies: Clinimetrics of Immune Mediated Neuropathies (13:55 - 14:50)
- **7.2** Hanna: The Role of Genetic Testing in Motor Neuron Disease (13:55 - 14:50)
- **8.2** Haller: Exercise Therapy in Myopathy (13:55 - 14:50)
- **9.2** Thenuwathavithi: Assessment of Autonomic Neuropathy (13:55 - 14:50)
- **10.2** Vajpayee: The Need for Transition (13:55 - 14:50)

Networking Break (14:50 - 15:15)

- **6.3** Hartung: Pathogenesis and Immunotherapy of Immune Mediated Neuropathies (15:10 - 16:05)
- **7.3** Berman: Biomarkers Relevant to ALS Therapy Development (15:10 - 16:05)
- **8.3** Thornton: Treatment of Myotonic Dystrophy (15:10 - 16:05)
- **9.3** Sandroni: Postural Orthostatic Tachycardia Syndrome (15:10 - 16:05)
- **10.3** Amato: Adult Limb-Girdle Dystrophy (15:10 - 16:05)
- **6.4** Schalk: Immunotherapy: What to do First, How to Start & Stop, Wear Off, Long-Term Considerations, Long-Term Outcome (16:05 - 17:00)
- **7.4** Rudnicki: Symptomatic Management of ALS (16:05 - 17:00)
- **8.4** Amato: The Treatment of Inflammatory Myopathy (16:05 - 17:00)
- **9.4** Vernino: Autoimmune Autonomic Neuropathy (16:05 - 17:00)
- **10.4** Dimachkie: Inclusion Body Myositis (16:05 - 17:00)

Opening Ceremony
GRAND BALLROOM CENTRE
(18:30 - 19:00)

Welcome Reception
EXHIBIT HALL
(19:00 - 21:00)

Registration Hours
MONDAY - 12:30 - 17:00

Poster Setup Hours
TUE:30 - 21:00

Speaker Ready Room Hours (Planner Office)
MONDAY, JULY 4, 2016 - 12:30 - 17:00
TUESDAY - 7:00 - 20:00

Wednesday, July 6, 2016

PLENARY

- **Genetics** — GRAND BALLROOM CENTRE
- **PL 1.1** Keynote Daniel MacArthur:GENOMIC APPROACHES TO DIAGNOSIS OF RARE MUSCLE DISEASE (8:00 - 9:00)
- **PL 1.2** Züchner: GENE DISCOVERY IN CHARCOT-MARIE-TOOTH NEUROPATHIES (8:55 - 9:30)
- **PL 1.3** Dowling: RNA Sequence and RNA Analysis (9:30 - 10:00)

Networking Break (10:00 - 10:30)

Poster Session (10:30 - 12:00)

INDUSTRY-SUPPORTED SYMPOSIUM (12:00 - 13:30)

WORKSHOP (WS) 1.0

- **WS 1.1** Imaging of Muscle — GRAND BALLROOM CENTRE
- **WS 1.2** Management of ALS — OSGOODE BALLROOM WEST
- **WS 1.3** Metabolic Myopathy — GRAND BALLROOM WEST
- **WS 1.4** Neuromuscular Disease — OSGOODE BALLROOM EAST
- **WS 1.5** Treatment of Myasthenia Gravis — GRAND BALLROOM EAST
- **1.1.1** Bonneman: Muscle Ultrasound (13:30 - 14:15)
- **1.2.1** Rudnicki: Symptomatic Treatment of ALS (13:30 - 14:15)
- **1.3.1** Tarnopolsky: Evaluation and Treatment of Pompe Disease (13:30 - 14:15)
- **1.4.1** Kamgoi: Neuromuscular Dysfunction (13:30 - 14:15)
- **1.5.1** Wolfe: General Treatment Approaches
- **1.1.2** Straub: THE APPLICATION OF MRI IN MUSCLE DISEASE (14:15 - 15:00)
- **1.2.2** Shneerson: End of Life Issues in ALS (14:15 - 15:00)
- **1.3.2** Viswing: DIETARY AND OTHER THERAPIES IN MUSCLE GLYCOGENOSES AND DISORDERS OF MUSCLE LIPID OXIDATION (14:15 - 15:00)
- **1.4.2** Flanigan: Treat MRD (14:15 - 15:00)
- **1.5.2** Iannaccone: Treatment of MD in the Paediatric Population (14:15 - 15:00)

Networking Break (15:00 - 15:30)

WORKSHOP (WS) 2.0

- **WS 2.1** Emerging Concepts in the Pathology and Clinical Management of Degenerative Cervical Myelopathy (DCM) — OSGOODE BALLROOM WEST
- **WS 2.2** MRI Studies in Peripheral Nerve Disease — GRAND BALLROOM EAST
- **WS 2.3** Outcomes in Hereditary Neuropathy — GRAND BALLROOM CENTRE
- **WS 2.4** Role of Skin Punch Biopsy — OSGOODE BALLROOM EAST
- **WS 2.5** Ultrasound in Peripheral Nerve Disease, Upper Limb - demonstrations — GRAND BALLROOM WEST
- **2.1.1** Feldman: Emerging Concepts in the Pathobiology of Degenerative Cervical Myelopathy, Epidemiology and Clinical Presentation (15:30 - 15:45)
- **2.2.1** Kollmer: Novel Processing Methods for Peripheral Nerve Imaging (15:30 - 16:15)
- **2.3.1** Reilly: Outcomes in CMT (15:30 - 16:15)
- **2.4.1** Sapeviano: Role of Skin Punch Biopsy in Clinical Practice (15:30 - 16:15)
- **2.5.1** Walker: Practical Demonstration and Discussion (15:30 - 17:00)
- **2.1.2** Anthony Burns: Clinical Implications, Outcomes and Rehabilitation Pathways (15:45 - 16:00)
- **2.1.3** Kalsi-Ryan: Understanding Disease Severity Through Novel Surrogate Measurement Approaches in MTSCI (16:00 - 16:15)
- **2.1.4** Cohen-Adad: Advanced Techniques in Imaging Spinal Degenerative Myelopathy (16:15 - 16:30)
- **2.2.2** Nanaghi: Challenges in MRI Studies of Peripheral Nerves (16:15 - 17:00)
- **2.3.2** Shy: Monitoring Hereditary Neuropathies in Clinical Trials (16:15 - 17:00)
- **2.4.2** Polydefkis: Role of Skin Punch Biopsy As a Research Outcome Measure (16:15 - 17:00)
- Panel Discussion (16:30 - 17:00)

INDUSTRY-SUPPORTED EVENING SEMINAR (17:15 - 18:15)

Thursday, July 7, 2016

INDUSTRY-SUPPORTED SEMINARS (7:00 - 8:00)

PLENARY
Hot Topics
GRAND BALLROOM CENTRE

- **PL 2.1** Feldman: Stem Cell Therapy in ALS (8:00 - 8:15)
- **PL 2.2** Wolfe: Results of the Thymectomy Trial in Myasthenia Gravis (8:15 - 8:30)
- **PL 2.3** Howard: Regain: A Randomized, Double-Blind, Placebo-Controlled Multi-Center Phase 3 Study Of The Safety And Efficacy Of Eculizumab In Subjects With Refractory Generalized Myasthenia Gravis (8:30 - 8:45)
- **PL 2.4** Barohn: APPROACH TO PATIENT-CENTERED OUTCOMES RESEARCH (8:45 - 9:00)
- **PL 2.5** Bonnemann: Do We Still Need Muscle Biopsy in the Era of Ultrasound? (9:00 - 9:15)
- **PL 2.6** Dimachkie: Therapeutic Approaches to Inclusion Body Myositis (9:15 - 9:30)
- **PL 2.7** Adams: Treatment of Amyloid Neuropathy (9:30 - 9:45)
- Panel Discussion (9:45 - 10:00)

Networking Break (10:00 - 10:30)

Poster Session (10:30 - 12:00)

Free Lunch Time

WORKSHOP (WS) 3.0

- **WS 3.1** Challenges in Design of Investigator-Initiated Research — OSGOODE BALLROOM WEST
- **WS 3.2** Diagnosis and Treatment of Myotonic Dystrophy — GRAND BALLROOM EAST
- **WS 3.3** Modern Concepts in Myasthenia Gravis — GRAND BALLROOM CENTRE
- **WS 3.4** Small Fibre Neuropathy — OSGOODE BALLROOM EAST
- **WS 3.5** Ultrasound in Peripheral Nerve Disease, Lower Limb — GRAND BALLROOM WEST
- **3.1.1** Bunche: CHALLENGES FOR INVESTIGATOR INITIATED TRIALS AND FOR COMMERCIAL MULTICENTER TRIALS (10:30 - 14:15)
- **3.2.1** Thornton: How to Treat Myotonic Dystrophy (10:30 - 14:15)
- **3.3.1** Yoan: Molecular Diagnostics in the Neuromuscular Clinic (10:30 - 14:15)
- **3.4.1** Adams: AMYLOID NEUROPATHY AS A MODEL OF SMALL FIBRE NEUROPATHY (10:30 - 14:15)
- **3.5.1** Walker: Practical Demonstration and Discussion (10:30 - 15:00)
- **3.1.2** Barohn: Transatlantic Challenges (14:15 - 15:00)
- **3.2.2** Morkye: Current Knowledge About Myotonic Dystrophy (14:15 - 15:00)
- **3.3.2** Flanigan: TBC (14:15 - 15:00)
- **3.4.2** Lacomi: Diagnosis of Small Fibre Neuropathy (14:15 - 15:00)

Networking Break (15:00 - 15:30)

WORKSHOP (WS) 4.0

- **WS 4.1** Bioinformatics and Clinical Research — GRAND BALLROOM WEST
- **WS 4.2** Complications Over Long-Term Skin Biopsy Sites — GRAND BALLROOM WEST
- **WS 4.3** Genetics of Hereditary Polyneuropathy — GRAND BALLROOM EAST
- **WS 4.4** Outcome Measures in Inflammatory Neuropathy — GRAND BALLROOM CENTRE
- **WS 4.5** Primer for Genetic Testing — OSGOODE BALLROOM EAST
- **4.1.1** Sherman: Technology Platforms for Clinical Research (15:30 - 16:15)
- **4.2.1** Amato: NERVE BIOPSY ARE RARELY NEEDED (15:30 - 16:15)
- **4.3.1** Züchner: Overview of Genetics of Hereditary Polyneuropathy (15:30 - 16:15)
- **4.4.1** Merkies: What the Peripheric Study Taught Us (15:30 - 16:15)
- **4.5.1** Reilly & Rawling: Evaluation of Variants of Unknown Significance (15:30 - 16:15)
- **4.1.2** Katz: Using the Electronic Medical Record for Research (16:15 - 17:00)
- **4.2.2** Dyck: It Is Valuable (16:15 - 17:00)
- **4.3.2** Saporta: Cellular Reprogramming and Inherited Peripheral Neuropathies - Perspectives and Challenges (16:15 - 17:00)
- **4.4.2** Léger: How We Should Assess Inflammatory Neuropathy (16:15 - 17:00)
- **4.5.2** Medne - Clinical Whole Exome Sequencing (16:15 - 16:25) Amburgey - Gene Panels (16:25 - 16:45)
- Discussion (16:45 - 17:00)

INDUSTRY-SUPPORTED EVENING SEMINAR (17:15 - 18:15)

Friday, July 8, 2016

LATE BREAKING NEWS
GRAND BALLROOM CENTRE
Nowak: Phase 2 Trial of Rituximab in Myasthenia Gravis: Study Update (7:00 - 7:20)
England: Neurological Complications on Zika Virus (7:20 - 7:40)
Nascimento: Guillain-Barré Syndrome and Variants Associated With Zika Virus Outbreaks (7:40 - 8:00)

PLENARY
Muscular Dystrophy
GRAND BALLROOM CENTRE

- **PL 3.1** Keynote Duan: Gene Therapy for Muscular Dystrophy (basic science) (8:00 - 8:30)
- Martin: RNA Therapeutics for Dystrophic Muscular Dystrophy (8:30 - 9:00)
- **PL 3.2** Thornton: Antisense Therapy for Myotonic Dystrophy (9:00 - 9:30)
- **PL 3.3** Cohn: CRISPR Based Gene Editing for Muscular Dystrophy (9:30 - 10:00)

Muscular Dystrophy Canada Presentation (10:00 - 10:05)

Networking Break (10:00 - 10:30)

Poster Session (10:30 - 12:00)

INDUSTRY-SUPPORTED SYMPOSIUM (12:00 - 13:30)

WORKSHOP (WS) 5.0

- **WS 5.1** Approach to Muscular Dystrophies — GRAND BALLROOM CENTRE
- **WS 5.2** Interrupting Neuromuscular Cases — GRAND BALLROOM EAST
- **WS 5.3** Diagnosis and Treatment of Diabetic Neuropathy — OSGOODE BALLROOM WEST
- **WS 5.4** Neuropathic Pain — GRAND BALLROOM WEST
- **WS 5.5** Outcome Studies in Myasthenia Gravis — OSGOODE BALLROOM EAST
- **5.1.1** Bonnemann & Straub: The Clinicians Approach to Limb Girdle Muscular Dystrophies Straub - LGMD (13:30 - 14:15) Bonnemann - Congenital Muscular Dystrophies (14:15 - 15:00)
- **5.2.1** Interesting Neuromuscular Case Presentations & Discussions (13:30 - 15:00)
- **5.3.1** Perkins: Diagnosis of DSP (13:30 - 14:15)
- **5.4.1** England: The Role of Guidelines in Decisions on Treatment (13:30 - 14:15)
- **5.5.1** Barnett Tapia: Myasthenia Gravis Impairment Index (13:30 - 14:15)
- **5.3.2** Lewis: Omega 3 Oil & Results in the Study (14:15 - 15:00)
- **5.4.2** Trivedi: Update on Treatment of Neuropathic Pain (14:15 - 15:00)
- **5.5.2** Ted Burns: Review of Current MG Scales (14:15 - 15:00)

Networking Break (15:00 - 15:30)

WORKSHOP (WS) 6.0

- **WS 6.1** ALS Overlap Syndromes — GRAND BALLROOM EAST
- **WS 6.2** Cramps in Neuromuscular Disease — GRAND BALLROOM CENTRE
- **WS 6.3** Diabetic Neuropathy — OSGOODE BALLROOM EAST
- **WS 6.4** Peripheral Nerve Tumors — OSGOODE BALLROOM WEST
- **WS 6.5** Ultrasound of Muscle and Nerve — GRAND BALLROOM WEST
- **6.1.1** Rogaeva: Genetic Aspects of ALS Overlap Syndromes (15:30 - 16:15)
- **6.2.1** Katzberg: Treatment of Muscle Cramps (15:30 - 16:15)
- **6.3.1** Russell: Epidemiology and Pathophysiology of Diabetic Neuropathy (15:30 - 16:15)
- **6.4.1** Grisold: Lymphoma and Other Peripheral Nerve Tumors (15:30 - 16:15)
- **6.5.1** Shook: Neuromuscular Physicians Should Perform NM Ultrasound (15:30 - 16:15)
- **6.1.2** Tartaglia: Clinical Aspects of ALS Overlap Syndromes (16:15 - 17:00)
- **6.2.2** Silvestri: Assessment Muscle Cramps (16:15 - 17:00)
- **6.3.2** Bril: Treatment of Diabetic Neuropathy (16:15 - 17:00)
- **6.4.2** Zadeh: Neurofibromatosis 1 and Malignant Transformation of Peripheral Nerve Sheath Tumors (16:15 - 17:00)
- **6.5.2** Pradyo: Radiologists Should Perform NM Ultrasound (16:15 - 17:00)

Congress Dinner
(18:30 - 22:00)

Poster Setup Hours
7:00 - 8:00

Speaker Ready Room Hours (Planner Office)
7:00 - 17:00

Saturday, July 9, 2016

INDUSTRY-SUPPORTED SEMINARS (7:00 - 8:00)

PLENARY
Motor Neuron Disease
GRAND BALLROOM CENTRE

- **PL 4.1** Keynote: Benatar: ALS Therapy Development: Challenges and Opportunities (8:00 - 9:00)
- **PL 4.2** Petrucelli: Biology of C9orf72 Disease (9:00 - 9:30)
- **PL 4.3** Kissel: Antisense Therapy for Spinal Muscular Atrophy (9:30 - 10:00)

Networking Break (10:00 - 10:30)

Poster Session (10:30 - 12:00)

INDUSTRY-SUPPORTED SYMPOSIUM (12:00 - 13:30)

WORKSHOP (WS) 7.0

- **WS 7.1** Autoantibodies in Neuromuscular Disease — GRAND BALLROOM CENTRE
- **WS 7.2** Evaluation of Variants of Unknown Significance — OSGOODE BALLROOM EAST
- **WS 7.3** Inclusion Body Myopathy — GRAND BALLROOM EAST
- **WS 7.4** Modern Concepts in Spinal Muscular Atrophy — GRAND BALLROOM WEST
- **WS 7.5** Update on FSHD — OSGOODE BALLROOM WEST
- **7.1.1** Querol: IgG4 Autoantibodies Related to Neuromuscular Diseases: Therapeutic Implications (13:30 - 14:15)
- **7.2.1** Reilly: Nerve (13:30 - 14:15)
- **7.3.1** Dimachkie: General Treatment Approaches (13:30 - 14:15)
- **7.4.1** Iannaccone: SMA Today (13:30 - 14:15)
- **7.5.1** Tawil: Recent Concepts in FSHD (13:30 - 14:15)
- **7.1.2** Mammen: Is It All About the Antibodies (14:15 - 15:00)
- **7.2.2** Baeser: Muscle (14:15 - 15:00)
- **7.3.2** Amato: Ongoing Developments in IBM (14:15 - 15:00)
- **7.4.2** Kissel: Update on SMA (14:15 - 15:00)
- **7.5.2** Statland: Clinical Presentation in FSHD (14:15 - 15:00)

Networking Break (15:00 - 15:30)

WORKSHOP (WS) 8.0

- **WS 8.1** Exercise Therapy for Metabolic Myopathies — OSGOODE BALLROOM EAST
- **WS 8.2** How To Fit Investigator-Initiated Trials, PCORI — OSGOODE BALLROOM WEST
- **WS 8.3** Metabolic Neuropathies — GRAND BALLROOM WEST
- **WS 8.4** Outcome Measures in Neuromuscular Disorders — GRAND BALLROOM CENTRE
- **WS 8.5** Treatment of Muscular Dystrophy — GRAND BALLROOM EAST
- **8.1.1** Haller: Exercise Therapy in Mitochondrial Disorders (15:30 - 16:15)
- **8.2.1 Barohn: WHY PATIENT-CENTERED OUTCOMES RESEARCH?** (15:30 - 16:15)
- **8.3.1** Smith: Neuropathy in Pre-Diabetes & The Metabolic Syndrome (15:30 - 16:15)
- **8.4.1** Lewis: Best Outcome Measures to Use for NM Patients (15:30 - 16:15)
- **8.5.1** Flanigan: Gene-Directed Treatment of Muscular Dystrophy (15:30 - 16:15)
- **8.1.2** Viswing: EXERCISE TRAINING AND PATHOPHYSIOLOGY OF EXERCISE IN METABOLIC MYOPATHIES (16:15 - 17:00)
- **8.2.2** Bunche: Investigator-Initiated Clinical Trials (16:15 - 17:00)
- **8.3.2** Pasnoor: Neuropathies in Systemic Disease (16:15 - 17:00)
- **8.4.2** McDonald: Outcome Measures in Muscular Dystrophy (16:15 - 17:00)
- **8.5.2** Campbell: Non-Gene Directed Treatment of Muscular Dystrophy (16:15 - 17:00)

Closing Ceremony
(17:00 - 18:00)

Poster Setup Hours 7:00 - 8:00
Poster Take Down Hours 15:30 - 17:00

Speaker Ready Room Hours (Planner Office)
7:00 - 17:00